Biovica establishes office in Boston

Biovica opens an office in Boston, the first office in the US. Pontus Nobréus, Business Development Director, will be heading up the office and will be based in Boston from 1st of January 2019.

The office will be located in west Boston. The location is chosen since Boston is an important biotech hub in the US with Biovica collaboration partners, such as Dana Farber Cancer Institute, in the nearby area.

USA is the single largest market for Biovica and, most important market. Biovica has previously started a US subsidiary in order to operate in the United States. It is important for us that we have the presence when we enter a phase where we will bring the product to the US market. Now, we take the next step by establishing staff in Boston, Massachusetts. This allows us to have a daily presence in our most important market. Managing projects in order to achieve reimbursement and develop commercial partnerships is of course facilitated by the presence and market knowledge that it provides. Pontus Nobréus, Business Development Director, will be based in Boston from 1/1 2019.

“By establishing an office in the biotech hub Boston, we shorten the distance to our customers and partners. This is an important milestone in the process of commercializing DiviTum and fulfilling our vision: Best treatment for cancer patients from day one!” says Anders Rylander, CEO, Biovica International AB.

“With local presence, we will be able to increase our business development activities in the US. I look forward to continue the collaboration with our existing partners, as well as establish new commercial opportunities for Biovica.” says Pontus Nobréus, Business Development Director, Biovica International AB.

Release

More information:

Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,
E-mail: anders.rylander@biovica.com

About Biovica

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.

Read more: www.biovica.com

2018-12-16T00:48:58+00:00 December 4th, 2018 08:00|News|